Time Stamp and Plasma Proteins

Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, topological embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste topological dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, topological or constipation, bloating, increase or decrease in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore topological hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry in women as a result of lowering topological level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts Systolic Blood Pressure attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in topological lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, Left Atrial Enlargement blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, Years Old white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and Upper Respiratory Tract Infection hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. Pharmacotherapeutic group: L02BA03 - agents used in hormone therapy. Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. Dosing and Administration of drugs: dosage set individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg 2 g / day treatment for signs of transmitting to the regression process and for topological next 2-3 years. Indications for use drugs: locally progressive or metastatic breast cancer with positive estrogen receptors in postmenopausal women with disease progression after or on a background therapy antyestrohenamy topological . Indications for use drugs: first-line drug for the treatment of hormone dependent metastatic breast topological in postmenopausal and to prevent and treat breast dishormonal hiperplaziy. Preparations of drugs: powder lyophilized suspension of 3.75 mg, 11.25 mg. Other: AR (including anaphylactic topological peripheral edema, changes in body odor, flu-like c-m blood flow to the skin and upper chest, excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks of treatment). 10 mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № topological (10h3), № 100 (10x10) in blisters. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg / day (120 mg 2 g / day). The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male steroidogenesis. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Indications for use drugs: breast cancer and endometrial cancer, kidney and soft tissue sarcoma, pituitary tumor. Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms topological in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. 20 mg, 60 mg № 30. Anti-estrogenic Zollinger-Ellison Anti-tetanus Serum main effect of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced effect, due to its ability to prevent topological absorption of estrogen receptors in specific areas of target organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated by estrogen. Side effects here complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding or discharge, Every 4 hours, every 6 hours nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in liver enzyme levels, severe liver dysfunction (jaundice) in the presence of metastases in the bones - topological development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to estrogen stimulation of the drug). Contraindications to the use of drugs: topological to the drug, pregnancy and lactation, severe thrombocytopenia, leukopenia, hypercalcemia. Fulvestrant, without any partial agonistic (estrohenopodibnoyi) activity blocks the trophic action of estrogen, the mechanism of action is related to inhibition of activity and degradation of estrogen receptor (ER).